The two membrane-bound proteins, focal adhesion kinase (FAK) and CD44, are involved in processes critical to cancer progression. FAK has an active role in angiogenesis, cell proliferation and cell apoptosis, whereas the heavily glycosylated CD44 has been implicated in cancer metastasis. Here, using short hairpin RNA (shRNA) against FAK and CD44, we demonstrate that simultaneous knockdown of both these genes inhibits cancer growth more efficiently than knockdown of either gene individually. Plasmids targeting these genes or non-relative control sequences were constructed and delivered to ovarian cancer targets by biodegradable poly D,L-lactide-co-glycolide acid nanoparticles (PLGANPs). Nude mice were utilized in an intraperitoneal model of ovarian carcinomatosis to assess antitumor efficacy in vivo. Single gene knockdown resulted in significantly smaller tumors than those observed in the empty-vector control (P'so0.001). More importantly, knockdown of both genes resulted in tumors smaller than both the empty-vector group (Po0.0001) and the single gene knockdown groups (P'so0.001). Knockdown of both FAK and CD44 resulted in tumors with inhibited angiogenesis, reduced proliferation and increased apoptosis as compared with controls (P'so0.001) and single knockdown groups (P'so0.05). These results indicate that dual knockdown of FAK and CD44 in the tumors of patients with ovarian cancer may have an enhanced therapeutic effect, and point toward a mechanism involving the inhibition of angiogenesis, cellular proliferation and the induction of apoptosis.
INTRODUCTION
Ovarian cancer is the principal cause of death associated with gynecological malignancy.
1 This is primarily due to the late stage at which most cancers are diagnosed and the limited efficacy of therapies for advanced-stage patients. Although modest progress has been made, 5-year survival continues to be poor, highlighting a pressing need of new therapeutic strategies. 1, 2 Angiogenesis has vital role in the development and progression of cancer. In addition, the tumor sculpts the microenvironment by manipulating cell-cell and cell-matrix interactions so that they favor invasiveness and aggression. This is particularly prevalent in ovarian cancers, where tumor cells often spread throughout the pelvic cavity. Therefore, targeting key genes in angiogenesis and adhesion within the tumor may elicit antitumor effects.
Among the many genes involved in ovarian cancer, focal adhesion kinase (FAK) and CD44 stand out as exceptional targets for short hairpin RNA (shRNA)-mediated knockdown therapy. FAK, a 125-kDa non-receptor protein tyrosine kinase, is an important mediator of growth-factor signaling, proliferation, migration, invasion and survival in tumor cells. 3 In addition, it has a prominent role in angiogenesis. [4] [5] [6] Recently, FAK overexpression was documented in ovarian carcinoma, and has been correlated with poor clinical outcome. 3, 7 Importantly, knockdown of FAK expression can inhibit the growth of ovarian cancer. 8 In comparison, CD44 is a transmembrane protein involved in cell adhesion, migration and lymphocyte function. CD44 is the major receptor of hyaluronan 9 and distributed widely in normal and tumor tissues. 10 However, previous studies have indicated that CD44 is overexpressed in ovarian cancer. 11 In addition, CD44 was identified as a surface marker of cancer stem cells in ovarian cancer 12 and knockdown of CD44 in ovarian cancer results in slowed growth. 13 Gene therapy holds promise for the treatment of a wide range of diseases, including cancer. RNA interference has been exploited as a tool to silence the expressions of functionally relevant tumor genes and holds great promise in conjunction with gene therapy.
14 Current studies are limited in that only single genes have been targeted for knockdown. Many genes are expressed abnormally in cancer, however, and simultaneously targeting two or more relevant tumor-associated genes may be more effective than targeting the single gene alone. Nevertheless, safe and effective gene carriers are critical to the success of gene therapy. Non-viral delivery systems are advantageous due to their low cytotoxicity, low immunogenicity and improved safety profile when compared with that of viral vectors. In recent years, poly (D,L-lactide-co-glycolide acid) (PLGA) nanoparticles (PLGANPs) have attracted considerable attention and interest due to their low toxicity, excellent biodegradability and biocompatibility. It has been suggested that PLGANPs can deliver therapeutic agents directly into the cytoplasm and nucleus of tumor cells, avoiding the endo-lysosomal pathway entirely. 15, 16 Finally, PLGANPs have been used in conjunction with shRNA to both efficiently express and knockdown genes in tumor cells with limited toxicity. 16, 17 We therefore chose to silence the expressions FAK and CD44 simultaneously in SKOV3 (ovarian) tumors using a recombinant plasmid vector based on shRNA encapsulated with PLGANPs.
MATERIALS AND METHODS

Constructions of shRNA plasmid vectors
Three experimental constructs were designed targeting FAK (pshFAK), CD44 (pshCD44) or both genes (pshFAK-CD44). The fourth construct was designed as empty-vector sequence (pshHK) and 0.9% sodium chloride (NaCl) solution was used as controls. Four recombinant plasmids were synthesized by Genesil Biotechnology (Wuhan, China). Oligonucleotide sequences of FAK (sense, 5
0 -CACCAACCACCTGGGCCAGTATTATTTCAAGAC GATAATACTGGCCCAGGTGGTTTTTTTTG-3 0 ; antisense, 5 0 -AGCTCAAAAAAAA CCACCTGGGCCAGTATTATCGTCTTGAAATAATACTGGCCCAGGTGGTT-3 0 ) and CD44 (sense, 5
0 -TCCCGTATGACACATATTGCTTCTTCAAGACGGAAGCAA TATGTGTCATACTTTTTTG-3 0 ; antisense, 5 0 -AGCTCAAAAAAGTATGACACATAT TGCTTCCGTCTTGAAGAAGCAATATGTGTCATAC-3 0 ) were designed according to the design principle and previous studies. 8, 18 Sequence of HK (sense, 5
0 -GATCCGACTTCATAAGGCGCATGCTTCAAGACGGCATGCGCCTTATGAAGT CTTTTTTGTCGACA-3 0 ; antisense, 3 0 -GCTGAAGTATTCCGCGTACGAAGTTCTG CCGTACGCGGAATACTTCAGAAAAAACAGCTGTTCGA-5 0 ) was designed with no homology to any human gene and used as empty vector. PshFAK-CD44 was cloned into the pGensile-2 plasmid, which contains a kanamycin resistance gene. pGensile-2 plasmid was linearized with Eco31I, ligated with annealed oligonucleotide templates FAK or CD44 into the plasmid vector using T4 DNA ligase, respectively. The pGensile-FAK and pGensile-CD44 were double-digested with SalI and HindIII, respectively. Then large fragment of pGensile-FAK and small fragment of pGensile-CD44 were ligated overnight at 16 1C using T4 DNA ligase. Finally, the identity of recombinant plasmid dual expressing FAK and CD44 genes (pshFAK-CD44) was confirmed by DNA sequencing. PshFAK, pshCD44 and pshHK were designed according to methods similar to that described above. Each correct colony was cultured in Luria-Bertani broth containing 100 mg ml À 1 kanamycin. A large scale preparation of plasmid DNA was purified using an EndoFree Plasmid Giga kit (Qiagen, Chatsworth, CA) and dissolved in sterile endotoxin-free water at a concentration of 1 mg ml À 1 and stored at À 20 1C for future use.
PLGANPs preparation and characteristics
PLGANPs encapsulating different pshDNAs were prepared as previous described. 16, 19 Before large quantities of PLGANPs loaded with pshFAK-CD44, pshFAK, pshCD44 or pshHK were generated, the procedure was optimized. Briefly, four pshDNAs were condensed via incubation with equivalent ploy-L-lysine (PLL with MW 25 kDa, Sigma, St Louis, MO) at 37 1C shaking table for 30 min. The complex of each pshDNA and PLL were added dropwise into a chloroform-acetone (9:1, v/v) mixture containing PLGA (LA:GA ¼ 75:25, MW 50 kDa, Department of Medical Polymers Shan Dong Institute, China), and was then emulsified by probe sonication in an ice bath under 20 W voltage for 20 s. The resulting primary emulsions were mixed with TE buffer containing polyvinyl alcohol (Sigma) and further emulsified under 40 W voltage for 20 s in an ice bath, thereby forming the aqueous/organic/aqueous phrase (W/O/W) double emulsion. The organic solvent in the double emulsion was removed by evaporation at 37 1C on a rotary evaporation instrument to isolate a suspension of PLGANPs loaded with pshDNA (pshDNA/PLGANPs). Finally, the suspension was centrifuged to remove the remained polyvinyl alcohol in the supernatants and then rediffused in sterile distilled water. This was repeated three times before all pshDNA/PLGANPs were stored at 4 1C. All preparations were used within 2 weeks.
The mean diameter (MD) of each pshDNA/PLGANPs was evaluated in triplicate by a laser scattering particle size analyzer (Zetsizer Nano ZS90, Malvern Instruments, Malvern, UK) the zeta potential, MD and polydispersity index of the nanoparticles were recorded. The entrapment efficiency (EE) and gene-loading rate (GLR) of each pshDNA/PLGANPs were calculated according to the quantity of entrapped pshDNA/PLGANPs, PLGA polymer and free pshDNA in supernatants. 20 All experiments were repeated for three times.
Cell culture and transfection conditions
The human ovarian serous cystadenocarcinoma cell line SKOV3 was obtained from American Type Culture Collection (ATCC, Manassas, VA) and incubated in a humidified atmosphere containing 5% CO 2 at 37 1C. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U ml À 1 penicillin G and 100 mg ml À 1 streptomycin, and passaged on reaching 70-80% confluence at a split ratio of 1:3.
SKOV3 cell (2 Â 10
5
) was plated in 6-well plates and cultured for 24 h to 30-40% confluence. Five microgram (5 mg) of each pshDNA (pshFAK-CD44, pshFAK, pshCD44 and pshHK) was diluted in 1 ml DMEM without antibiotics and serum. After 6 h, the medium was replaced with 2 ml DEME with fetal bovine serum and antibiotics. After 60-72 h of incubation, RNA and protein samples were collected for further assay.
Reverse transcription PCR
Total RNAs were isolated from cells or tumor tissues using TRIzol reagent (Invitrogen, Grand Island, NY). The primers were designed based on cDNA sequence with upstream primers 5 0 -CATTGCTGCTCGGAATGTT-3 0 and downstream primers 5 0 -ACTTCCATCCTCCCTGTCAA-3 0 for FAK, 5 0 -GCTCATA CCAGCCATCCAAT-3 0 and 5 0 -GAGGTCCTGTCCTGTCCAAA-3 0 for CD44, respectively. The predicted reverse transcription PCR (RT-PCR) products and the best annealing temperature for FAK and CD44 were 913 and 211 bp, and 54 and 55 1C, respectively. Five microliters (5 ml) of each RT-PCR product was electrophoresed on a 1% agarose gel. The housekeeping gene, GAPDH, was used as an internal control.
Western blot analysis
Cells or tumor tissues were lysed using RIPA lysis buffer (50 mM Tris-HCl, 0.25% sodium deoxycholate, 150 mM NaCl, 1% NP-40, 1 mM NaF, and 1 mM Na 3 V 4 ) containing 1 mM protein inhibitor (Sigma) and centrifuged at 12 000 r.p.m., 4 1C, for 30 min. Total protein concentrations were determined using Bio-Rad protein assay (Hercules, CA). Equal amounts of proteins (FAK and CD44) were separated on 8 and 10% SDS-PAGE gels, respectively, and transferred onto polyvinylidene difluoride membranes (Bio-Rad). After being blocked with 5% non-fat milk 2 h, membranes were immunoblotted with either rabbit polyclonal antibody against FAK (1:1000 dilution; Cell Signaling Technology, Boston, MA) or mouse monoclonal antibody against CD44 (1:500 dilution, mAb, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4 1C. Subsequently, the blots were incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at 37 1C (FAK: goat anti-rabbit IG, 1:10 000; ZSGB-BIO, Beijing, China) (CD44: goat anti-mouse IG, 1:3000; ZSGB-BIO). GAPDH was used as a loading control (1:1000 dilution; ZSGB-BIO). All bands were observed with an enhanced chemiluminescence detection system (Pierce Biotech, Rockford, IL).
Tumor xenograft model and treatment
All animal experiments were approved and supervised by the Institutional Animal Care and Use Committee of Sichuan University, in accordance with all regulations and guidelines of China. Female athymic BALB/c nude mice, 6-8 weeks old, housed in pathogen-free conditions and fed sterile chow, were used to establish the intraperitoneal carcinomatosis model modified from a previous study. 21 Briefly, SKOV3 cells (5 Â 10 6 cells in 100 ml of DMEM without serum and antibiotics) were injected subcutaneously into the right flank of each mouse. When the tumors reached 1 cm, they were collected and minced rapidly through six layers of stainless trap valves, yielding fragments with a diameter of no 41 mm. DMEM was added to a final volume of 12.5 ml. In all, 25 nude mice were inoculated intraperitoneal with 0.5 ml of the tumor suspension in the right lower quadrant with a 14-gauge needle. Mice were distributed randomly into five groups (five per group): (a) NS group, 100 ml 0.9% NaCl solution; (b) pshHK/PLGANPs group, 5 mg pshHK/100 ml PLGANPs; (c) pshCD44/PLGANPs group, 5 mg pshCD44/ 100 ml PLGANPs; (d) pshFAK/PLGANPs group, 5 mg pshFAK/100 ml PLGANPs; and (e) pshFAK-CD44/PLGANPs group, 5 mg pshFAK-CD44/100 ml PLGANPs. Systematic study of PLGANP kinetics demonstrates that 70% of the cargo is released after 48 h. 20 Accordingly, intraperitoneal administrations were initiated 5 days after inoculation, 2 days earlier than 7 after injection in a previous study. 21 Mice were injected every 3 days for a total of 12 treatments and were killed 3 days after the last administration. Intraperitoneal tumors were resected and weighed immediately to evaluate treatment efficacy.
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Alginate-encapsulated tumor cell assay An alginate-encapsulated assay was done in vivo to explore suppression of angiogenesis. Briefly, SKOV3 cells were suspended in a 1.5% solution of sodium alginate (Sigma) and added dropwise into a swirling solution of 250 mM CaCl 2 . Four alginate beads (containing 2 Â 10 5 tumor cells per bead) were implanted subcutaneously into an incision made on the dorsal side of each mouse. Ten BALB/c female nude mice were grouped and treated as described before. Treatment was initiated on the same day as bead implantation. After 2 weeks, beads were photographed during surgery.
Immunohistochemistry
Intraperitoneal tumors were fixed in 4% paraformaldehyde, embedded in paraffin and cut into 3-5 mm sections. Deparaffinized tumor sections were immersed in 10 mM citrate buffer (pH 6.0) and heated in an autoclave for 5 min in saturated steam for antigen retrieval. Endogenous peroxidase activity was quenched in 3% H 2 O 2 for 10 min, and non-specific binding was blocked with homeotypic non-immunoglobulin secondary antibody at 37 1C for 20 min. Sections were then incubated with the primary antibody against FAK (Cell Signaling Technology), CD44 (Santa Cruz Biotechnology), CD31 (ZSGB-BIO, Beijing, China) and Ki-67 (ZSGB-BIO, Beijing, China) at 4 1C overnight. The next day, sections were incubated with streptavidin-biotinhorseradish peroxidase complex at 37 1C for 40 min, followed by biotinylated secondary antibody at 37 1C for 40 min. Colorimetric detection was performed with diaminobenzidine.
Immunofluorescence staining
Apoptosis was evaluated by using a commercially available terminal deoxynucleotidyl transferase-mediated dUTP nickend labeling (TUNEL) kit (DeadEnd Fluorometric TUNEL System, Promega, Madison, WI). The apoptosis index was assessed by calculating the average percentage of green fluorescence-positive cells in 10 random fields from at least 3 sections for each group at Â400 magnification.
Toxicity evaluation
Adverse effects and toxicity, such as weight loss, ruffling of fur, skin ulceration, appetite and behavior changes, and cachexia were evaluated visually for each mouse. In addition, heart, liver, spleen, lung, kidney and pancreas sections were stained with hematoxylin and eosin (H&E) and evaluated for normal histology by independent pathologists.
Statistical analysis
Student's t-test for two-group comparisons and one-way ANOVA for multiple-group comparisons were performed depending on the assay. A P-value of o0.05 was defined as statistically significant. The Statistical Package for the Social Sciences 13.0 (SPSS, Chicago, IL) was used for all statistical analyses.
RESULTS
Characterization of PLGANPs MD, polydispersity index, EE and GLR for each pshDNA/PLGANP are shown in Table 1 . The EE and GLR were higher in our study than in previous studies. 16, 19, 22 Ultracentrifugation was used to remove the free plasmid DNA and polyvinyl alcohol in the supernatant as described previously. 22 Downregulation of FAK and CD44 expression in vitro To evaluate the expression of FAK and CD44 after treatment with the pshDNA/PLGANP in vitro, SKOV3 cells were collected at 60-72 h after transfections and analyzed by RT-PCR and western blot.
Semiquantitative RT-PCR indicated that expression of FAK mRNA was inhibited by 76 and 73% in the pshFAK-CD44/PLGANP and pshFAK/PLGANP groups, respectively, as compared with the pshHK/PLGANPs group (P'so0.001) (Figure 1a ). CD44 mRNA expression was decreased by 68 and 67% in the pshFAK-CD44/ PLGANP and pshCD44/PLGANP groups, respectively, as compared with the pshHK/PLGANPs group (P'so0.001) (Figure 1b) . There was no significant difference between the pshFAK/PLGANP and pshCD44/PLGANP groups, or between the pshHK/PLGANP and 0.9% NaCl groups. The density of RT-PCR bands was measured by Quantity One and was normalized with GAPDH ( Figure 1) .
Suppressions of FAK and CD44 at the protein level were observed in SKOV3 after treatment with pshFAK-CD44/PLGANPs in vitro (Figures 1c and d) . CD44 exists as multiple isoforms and is heavily modified/glycosylated after translation. 23 Therefore, CD44 protein appears at a wide range of molecular weights (80-250 kDa). The antibody used in this study yields band for CD44 at the molecular weight of 90 kDa. A clear decrease in FAK protein expression was observed in the pshFAK-CD44/PLGANP and pshFAK/PLGANP groups, compared with controls ( Figure 1c) . Likewise, CD44 protein also showed significant downregulation after treatment with pshFAK-CD44/PLGANPs and pshCD44/ PLGANPs (Figure 1d ). Western blot analysis confirmed the results observed via RT-PCR. Taken together, these results demonstrate that both FAK and CD44 can be effectively downregulated at both the RNA and protein level after treatment with loaded pshDNA/ PLGANPs in vitro.
PshFAK-CD44/PLGANPs inhibit tumor xenograft growth in nude mice To further assess the effectiveness of FAK and/or CD44 gene silencing in vivo, intraperitoneal tumors were established in nude mice. Tumor bearing mice were treated with 0.9% NaCl, pshHK/ PLGANPs, pshCD44/PLGANPs, pshFAK/PLGANPs or pshFAK-CD44/ PLGANPs every 3 days as described in Materials and methods. The mice were killed 3 days after the last nanoparticle injection. All tumors were collected and photographed carefully.
In all mice, tumor nodules were found scattered around the pelvis. These lesions varied in size, but were larger and more numerous in the two control groups (Figures 2a and b) . The average weight of intraperitoneal tumor lesions was 1.52 ± 0.23 g, 1.38±0.15 g, 0.71±0.11 g, 0.58±0.09 g and 0.29±0.14 g in the NS, pshHK/PLGANP, pshCD44/PLGANP, pshFAK/PLGANP and pshFAK-CD44/PLGANP groups, respectively (Table 2) . Tumor weight was reduced by 49 and 58% in pshCD44/PLGANP and pshFAK/PLGANP groups when compared with the pshHK/ PLGANPs group, respectively (P'so0.001). Most strikingly, the weight of tumors in the pshFAK-CD44/PLGANPs group was reduced by 79% when compared with the pshHK/PLGANPs group (P ¼ 1.33296E À 07, Po0.0001). Finally, tumor weight in pshFAK- Dual silencing FAK and CD44 in ovarian cancer L Zou et al CD44/PLGANPs group was suppressed by 50 and 59% when compared with the pshFAK/PLGANP and pshCD44/PLGANP groups, respectively (P ¼ 0.0013 and P ¼ 0.00016, respectively, P'so0.01; Figure 2c ). There was no significant difference between the 0.9% NaCl and pshHK/PLGANP groups, or between the pshCD44/PLGANP and pshFAK/PLGANP groups (P's40.05).
Suppressions of FAK and CD44 in vivo
Tumor sections of each treatment group were used for both RT-PCR and western blot analysis. The level of FAK mRNA in pshFAK-CD44/PLGANP and pshFAK/PLGANP groups was significantly reduced (77 and 75%, respectively) when compared with the pshHK/PLGANPs group (P'so0.001) (Figure 3a) . Similarly, CD44 message was reduced in the pshFAK-CD44/PLGANP and pshCD44/ PLGANP groups (72 and 70%, respectively) when compared with the pshHK/PLGANPs group ( Figure 3b ) (P'so0.001). Western blot confirmed these results on the protein level (Figures 3c and d) .
In addition, immunohistochemical staining of FAK in tumor tissues further demonstrated the suppression of FAK in the tumors of the pshFAK-CD44/PLGANP-and pshFAK/PLGANPtreated mice, as shown in Figure 3e . Likewise, immunohistochemical staining of CD44 in tumor tissues showed suppressions of CD44 expression in the pshFAK-CD44/PLGANP and pshCD44/ PLGANP groups (Figure 3e ). Together, these results indicate that FAK and CD44 were suppressed at both the RNA and protein level after treatment using shRNA encapsulated in PLGANPs in vivo.
Inhibition of angiogenesis by pshFAK-CD44/PLGANPs in vivo
Antiangiogenic therapies are important in the treatment of cancer. A growing body of literature supports a role for FAK during tumor angiogenesis. 4, 5 Likewise, CD44 acts as an important adhesive factor on the surface of vascular endothelial cells. We therefore sought to evaluate the effects of suppressing each of these proteins on angiogenesis in vivo. To do so, we measured microvessel density (MVD) in endothelial cells by staining for the vascular marker CD31. In addition, we performed an alginate encapsulation test to evaluate vessel formation in vivo. Inhibition of angiogenesis in the treated mice was indicated by alginate encapsulation test (Figure 4) . The alginate implants showed a significant reduction in the number of new vessels in the pshCD44/PLGANP, pshFAK/PLGANP and pshFAK-CD44/ PLGANP groups, compared with the control groups. The greatest reduction was observed in the pshFAK-CD44/PLGANPs group compared with those in pshFAK/PLGANPs or pshCD44/PLGANPs group, which is consistent with results of CD31 staining.
The above results indicate that angiogenesis within the human ovarian cancer xenografts was inhibited in mice treated with the pshCD44/PLGANPs, pshFAK/PLGANPs or pshFAK-CD44/PLGANPs shRNA bearing nanoparticles. Moreover, the effect was greatest in pshFAK-CD44/PLGANPs group, indicating a benefit to target both proteins simultaneously. In summation, we therefore suggest that the antitumor activity of pshFAK-CD44/PLGANPs is due, at least in part, to the inhibition of angiogenesis in our tumor model.
Inhibition of cell proliferation and the induction of cell apoptosis by pshFAK-CD44/PLGANPs in vivo
To further explore the mechanism of tumor suppression elicited by the pshFAK-CD44/PLGANPs in vivo, we measured their effects on other biological end points, including cell proliferation (Ki-67) and apoptosis (TUNEL).
Ki-67 staining was used to assess the effect of pshFAK-CD44/ PLGANPs therapy on tumor cell proliferation. The proliferation index was determined by taking the ratio of positive Ki-67 cells compared with the total number of cancer cells. Ki-67 expression was not impaired for either the NS or pshHK/PLGANP groups. In comparison, the percentage of Ki-67 cells was significantly reduced in the pshFAK-CD44/PLGANP, pshFAK/PLGANP and pshCD44/PLGANP groups, when compared with the two control groups (P'so0.001). Again, the most profound reduction in Ki-67 cells was observed in the tumors obtained from mice receiving pshFAK-CD44/PLGANPs treatment, compared with pshHK/ PLGANPs group (9.75 ± 1.76 versus 43.75 ± 6.62, Po0.0001; Figure 5a ). Furthermore, silencing both targets with the pshFAK-CD44/PLGANPs resulted in significantly less proliferation than observed in mice receiving either the pshFAK/PLGANPs or pshCD44/PLGANPs alone (P'so0.001; Figure 5a ).
An imbalance of cell proliferation with apoptosis can contribute to tumor growth and invasion. We therefore also performed TUNEL staining to assay for apoptotic cells in tumor tissues. A greater number of apoptotic cells were observed in the pshFAK-CD44/PLGANP, pshFAK/PLGANP and pshCD44/PLGANP groups when compared with controls (P'so0.001) (Figure 5b) . The greatest number of TUNEL-positive cells was observed in the pshFAK-CD44/PLGANPs group, and was significantly greater than in the groups targeting either FAK or CD44 alone (Po0.01; Figure 5b ).
Toxicity observation
Animal weight was measured every 3 days (Figure 6a ) and no significant differences in weight were observed in five groups. Furthermore, histological examination of heart, liver, spleen, lung and kidney did not reveal any significant differences between all groups (Figure 6b ). Dual silencing FAK and CD44 in ovarian cancer L Zou et al DISCUSSION By regulating the expression of genes involved in tumorigenesis, gene therapy offers a unique method to change the tumor and its microenvironment. Combining gene therapy with RNA interference, including siRNA and shRNA, is a powerful tool that can be used to downregulate targets involved in tumorigenesis. Plasmid vector-based shRNA was chosen here for its easy preparation, relative stability and sustained expression compared with siRNA. 24 shRNA has been successfully therapeutically used in many anticancer studies, including the treatment of ovarian cancer. 25, 26 Most of these studies, however, target a single gene among the many abnormally expressed genes upregulated in cancer. The benefit of targeting multiple genes simultaneously was highlighted in a recent study where targeting EphA2 in combination with the downstream, FAK, showed greater inhibition of ovarian cancer growth. 27 For this reason, we hypothesized that simultaneously knocking down the expression of two genes vital to tumorigenesis may increase the anticancer efficacy of therapy only targeting one gene. To test our hypothesis, we silenced the expressions of the two cancerassociated genes FAK and CD44, using shRNA carried on a recombinant plasmid and delivered by PLGA nanoparticles.
FAK is a non-receptor protein kinase expressed abundantly in the cytoplasm, and consists of a nuclear kinase domain, a C-terminal FAT domain and an N-terminal FERM domain. Activation of FAK influences multiple aspects of cellular behavior, including motility, integrin and focal contact turnover, survival 28, 29 and angiogenesis. 28 FAK is also implicated in manipulating the tumor microenvironment; 8 activation of FAK was observed in invasive ovarian cancer, but not in normal ovarian epithelium. 30 Additional studies continue to support this observation, 16, 3 and the silencing of FAK is currently being studied in the context of ovarian cancer.
31
CD44 belongs to a large family of proteins that have an important role in cell-cell and cell-matrix adhesion. 32 Specifically, CD44 is the primary receptor for hyaluronic acid, and as such, it has an essential role in cell adhesion and cell migration.
9 CD44 þ cells isolated from human breast tumors could recapitulate their original phenotype and perpetuate themselves. In ovarian cancer, CD44 is a cancer stem cell marker. 33 These characteristics make CD44 an ideal target for shRNA gene therapy. In both ovarian and colon cancers, silencing of CD44 suppresses tumor growth. 13, 34 In this study, we demonstrate that simultaneous silencing of FAK and CD44 with shRNA significantly inhibits the growth of Dual silencing FAK and CD44 in ovarian cancer L Zou et al human ovarian cancer xenografts in nude mice. In addition, silencing FAK or CD44 alone showed suppression of tumor growths compared with controls, similarly to previously reported results. 6, 13 We also confirm that FAK and CD44 have important roles in ovarian cancer and that they are good targets for gene therapy. Our most significant finding, however, is that silencing both FAK and CD44 simultaneously reduces tumor growth more substantially than targeting either target alone. This is the first report to indicate that silencing FAK and CD44 together can be used to treat ovarian cancer.
A safe and effective vector delivery system is essential to gene therapy. Although many viral vectors demonstrate high transduction efficiency, toxicity continues to be a concern during clinical application. 35 Over the last decade, improvements in nonviral vectors have given them some advantages over viral vectors. [36] [37] [38] During this time, various novel non-viral vectors have been developed and tested. 39, 40 PLGA is a relatively new carrier system being employed to deliver cargo to malignant tumors. 19, 22, 41 As a non-viral vector, PLGA is attractive for a number of reasons. First, PLGA particles are slowly released in vivo, which may increase the half-life and efficacy of the drugs or genes being delivered. Second, PLGA nanoparticles exhibit low cytotoxicity in vivo. 16, 42 Finally, PLGA is harmlessly biodegraded into CO 2 and H 2 O in vivo. We previously demonstrated that PLGA can be loaded in nanoparticles (PLGANPs) and used to deliver genes into tumor cells. 17, 43 In our present study, PLGANPs were used to deliver several recombinant plasmids silencing FAK and/or CD44 genes to SKOV3-derived tumors in nude mice. As a result, the expression of FAK and CD44 was lessened in the tumors receiving the knockdown shRNAs when compared with the control tumors as indicated by RT-PCR, western blot and immunohistochemistry. The biologic features of PLGA have been studied extensively. The silencing of FAK and CD44 suppressed tumor growth in vivo, indicating that PLGANPs can successfully deliver a large multi-component plasmid to the tumor. No toxicity was observed in the treated mice, suggesting that the PLGANPs are safe. However, further toxicity assessment should be performed.
To elucidate the mechanism of growth suppression in the FAK and CD44 knockdown tumors, angiogenesis was assessed by CD31 staining and alginate encapsulation test. A significant reduction in new vessels was observed in tumors receiving the pshFAK/PLGANPs and pshCD44/PLGANPs. This effect was more pronounced when both FAK and CD44 were silenced simultaneously (pshFAK-CD44/PLGANPs). A role for FAK in angiogenesis has already been described, [4] [5] [6] but the role of CD44 is less clearly understood. It is likely that CD44 is involved in the adhesion of endothelial cells to the vascular matrix, potentially explaining why we observed less vascularization in the pshCD44/PLGANP-treated tumors. This is consistent with a prior report that described how the multimeric signaling complex of CD44 and its related receptor tyrosine kinases are involved in angiogenesis. 9 Induction of apoptosis in endothelial cells may be one mechanism by which CD44 knockdown can influence tumor angiogenesis. Cells treated with siRNA against CD44 exhibit increased apoptosis compared with control siRNA. 13 In addition, preventing the binding of hyaluronidase to CD44 increases apoptosis. 33 However, the actual role of CD44 in angiogenesis is unclear and further study is needed to address this question. Finally, Ki-67 staining and TUNEL assays suggest that silencing FAK and CD44 leads to a significant Dual silencing FAK and CD44 in ovarian cancer L Zou et al reduction in cell proliferation and corresponding increase in apoptosis. Taken together, knockdown of FAK and CD44 in the tumor results in impaired growth, which results from inhibition of antiangiogenesis, a decrease in proliferation and an induction of apoptosis. However, further experimentation is needed to discern the full contribution of each mechanism to the antitumor activity of the PLGANPs.
In conclusion, we demonstrate that using RNA interference against FAK and CD44 simultaneously has a more potent antitumor affect than targeting either gene alone. This is mediated in part by inhibiting angiogenesis, reducing proliferation and inducing apoptosis in the cancer cells. Finally, given the strong antitumor effect and lack of toxicity observed, we assert that PLGANPs can be used to deliver shRNA to ovarian tumors.
